Trenbolone Dermal Exposure: What New Doping Tests Show

A new peer-reviewed study shows that trace dermal exposure to trenbolone and metenolone can produce detectable urinary findings. In controlled experiments published September 18, 2026, healthy male volunteers received a single 50-microgram application of either steroid to the forearm. Both substances, or their metabolites, were later detected in urine from every participant. Trenbolone’s main marker, epitrenbolone, remained detectable for up to three days. One metenolone metabolite persisted for more than a week in one volunteer.

The findings matter because anti-doping laboratories increasingly assess claims involving accidental transfer, contaminated topical products, or unintended skin exposure. The paper does not show that routine contact with an anabolic steroid causes a positive test, nor can it determine whether any individual result came from intentional use. Instead, it provides controlled pharmacology data that can help experts assess whether a proposed exposure route is chemically plausible.

This study examined detection science, not performance effects, medical treatment, or safe exposure levels. Trenbolone and metenolone remain prohibited anabolic-androgenic steroids in anti-doping rules.

What the September 2026 study actually tested

The research team included scientists from the Institute of Biochemistry at German Sport University Cologne, the National Center for Scientific Research “Demokritos” in Greece, and the European Center for Emerging Doping Agents. Their study was published in the Journal of Analytical Toxicology, a peer-reviewed journal focused on drug detection, forensic chemistry, and toxicology.

The investigators studied two anabolic-androgenic steroids, or AAS. AAS are synthetic compounds related to testosterone that can activate androgen receptors and affect muscle, reproductive, and metabolic biology. The compounds were trenbolone, a potent anabolic steroid widely recognized in veterinary and illicit-use contexts, and metenolone, another anabolic steroid associated with anti-doping cases.

Each participant received a single 50-microgram dermal application to the forearm. Researchers then collected urine samples and analyzed them with liquid chromatography coupled with high-resolution tandem mass spectrometry, or LC-HRMS/MS. This method separates compounds in a sample and identifies them by their mass and fragmentation pattern.

The dose provides important context. A 50-microgram research exposure is extremely small compared with quantities often discussed in illicit steroid use. The experiment was designed to determine whether highly sensitive laboratory methods could detect urinary traces after skin absorption. It was not designed to model consumer products, workplace exposure, gym contact, or deliberate administration.

The study also compared urinary metabolite profiles after dermal exposure with samples collected after oral steroid administration. This comparison can help laboratories assess whether the exposure route changes the chemical markers found in urine.

What happened after dermal trenbolone exposure?

Trenbolone-related findings appeared in the urine of all participants who received the dermal application. The dominant marker was epitrenbolone, an established metabolite of trenbolone. The highest reported epitrenbolone concentration was 2.6 nanograms per milliliter.

Researchers reported a detection window of up to three days after the single application. In these study conditions, the analytical signal could be identified in urine for as long as three days. That does not mean every person will have the same window. Detection can vary with the amount absorbed, skin site, formulation, skin integrity, metabolism, urine concentration, sample timing, and laboratory sensitivity.

The result shows that a very small dermal exposure can pass through several biological steps: the steroid crosses the skin, enters circulation, undergoes metabolism, and produces a urinary concentration the laboratory can distinguish from background noise.

That pathway does not mean casual contact automatically leads to a sporting-rule violation. A laboratory finding must be considered alongside the measured concentration, identified metabolites, sample quality, the athlete’s explanation, and applicable anti-doping procedures. The experiment demonstrates possibility, not frequency.

Epitrenbolone is especially important because anti-doping laboratories often identify metabolites rather than relying only on the original parent drug. Metabolites can remain in urine after the parent compound has declined and may offer a more reliable signature of exposure.

What happened after dermal metenolone exposure?

Metenolone also produced detectable urinary findings in every participant who received the dermal microdose. Reported maximum concentrations ranged from 0.1 to 1.2 nanograms per milliliter. These concentrations were low, but the analytical method was sensitive enough to identify the compound or its metabolites.

The most notable finding involved a sulfoconjugated metenolone metabolite. Sulfoconjugation is a normal metabolic process in which the body attaches a sulfate group to a compound. This can increase water solubility and help the body excrete the chemical in urine.

In one volunteer, the sulfoconjugated metenolone metabolite remained detectable for more than seven days. This does not mean metenolone will remain detectable for more than a week in every person. One participant cannot define a population-wide detection window. However, the finding shows that some metabolites may outlast the parent compound and that laboratories may need to monitor more than one urinary marker.

The result also shows why a simple “half-life” explanation is not enough for drug testing. A steroid’s biological half-life describes how quickly its concentration falls in a particular compartment. A laboratory detection window also depends on metabolism, conjugation, excretion, assay sensitivity, and the threshold used to report a finding.

The table summarizes controlled observations from the study. It should not be used to predict a specific person’s test result.

Why the route of exposure changes the interpretation

Drug testing is often discussed as if a compound has one fixed detection period. In practice, the route of administration can affect both concentrations and metabolite patterns. Oral administration exposes a substance to the digestive tract and liver before it reaches the rest of the body. Dermal exposure begins at the skin barrier and may lead to slower, smaller, or more variable systemic exposure.

Skin is not a uniform membrane. Absorption can vary with skin thickness, local blood flow, temperature, hydration, inflammation, hair follicles, and skin damage. The steroid’s chemical properties also matter. Lipid solubility and formulation can affect whether a compound crosses the outer skin layer.

The authors noted that transdermal absorption is driven substantially by the amount applied. This is important when evaluating contamination claims. “Contact” can describe very different situations. A controlled 50-microgram application is not the same as briefly touching a surface with an unknown trace, nor is it the same as repeatedly handling a concentrated preparation.

Forensic interpretation requires more than asking whether skin absorption is possible. Relevant questions include:

• How much material was plausibly present?
• How long was the skin in contact with it?
• Was the skin intact or damaged?
• What formulation or carrier was involved?
• Which parent compound and metabolites were detected?
• What concentrations were measured?
• How soon after the claimed exposure was the sample collected?
• Does the pattern resemble the proposed route of exposure?

The new study helps address the last question, but only under the tested conditions.

What the findings mean for anti-doping laboratories

Anti-doping laboratories need validated methods that detect prohibited substances at very low concentrations. They also need reference data to distinguish plausible explanations from unsupported ones. The new paper contributes to both goals.

First, it confirms that dermal exposure can produce measurable urinary evidence for trenbolone and metenolone. That matters when laboratories investigate claims involving contaminated topical products or accidental skin transfer.

Second, it adds information on metabolite timing. Trenbolone was mainly represented by epitrenbolone, while metenolone produced a more prolonged signal from a sulfoconjugated metabolite in one participant. Marker identity and timing can help toxicologists compare a sample with known exposure scenarios.

Third, the study demonstrates the value of high-resolution analytical methods. Standard screening may identify a suspicious signal, but confirmation usually relies on a more detailed chemical pattern. LC-HRMS/MS can detect low-level compounds and compare their fragmentation behavior with reference materials.

These methods do not remove uncertainty. Analytical science can establish that a compound or metabolite is present, but it cannot always establish intent by itself. Anti-doping systems use additional procedural evidence, including sample collection records, chain of custody, athlete explanations, therapeutic-use exemptions where relevant, and specialized expert review.

Readers interested in how newer anabolic compounds are identified can compare this paper with GLP1Place’s coverage of LGD-4033 metabolite detection. That earlier study involved ligandrol, a selective androgen receptor modulator, rather than trenbolone or metenolone. Both reports show how drug testing increasingly relies on long-lived or route-specific metabolites rather than the original compound alone.

Are trenbolone and metenolone prohibited in sport?

Yes. Trenbolone and metenolone are listed as anabolic-androgenic steroids under the World Anti-Doping Code. The 2026 prohibited list identifies both among substances prohibited at all times, including during and outside competition. The current list also prohibits other substances with a similar chemical structure or biological effect.

USADA explains that the prohibited list applies to athletes subject to the World Anti-Doping Code and is updated through the global anti-doping framework. The list is a regulatory document, not a clinical safety assessment. A compound may be prohibited because of its potential to enhance performance, threaten athlete health, or violate the spirit of sport.

A prohibited substance does not become permissible simply because exposure was dermal, low-level, or unintended. At the same time, anti-doping rules include processes for reviewing adverse analytical findings and considering evidence about how a substance entered the body. The purpose of the study is to improve that review, not to create a universal defense.

For background on broader grey-market steroid risks, GLP1Place previously examined a documented anabolic steroid trafficking case. That article focused on manufacturing, labeling, and distribution risks. The present study addresses a separate laboratory question: what urine testing can show after very small dermal exposure.

What the study does not show

The paper is informative, but its limitations are substantial. The study involved healthy male volunteers, a small controlled exposure, one application site, and a single dose. It did not test women, adolescents, older adults, people with liver or kidney disease, or people taking other drugs.

It also did not examine repeated exposure. Repeated applications could change urinary concentrations and extend the appearance of metabolites. The study did not model commercial creams, gels, oils, patches, contaminated clothing, shared equipment, workplace conditions, or skin-to-skin transfer efficiency.

The sample size and exposure design limit generalization. A result observed in every participant under a controlled protocol shows that the pathway is possible. It does not show how often that pathway occurs in the real world.

The study also cannot determine intent. A positive analytical finding may be consistent with more than one exposure route. The paper provides laboratory evidence for interpreting possibilities, not a method for assigning blame or proving deliberate use.

Finally, detection is not the same as harm. The study was not designed to assess clinical effects from dermal trenbolone or metenolone. It should not be used to infer that trace exposure is medically harmless or that larger exposure is safe.

Why this matters beyond competitive sport

The findings may also matter for forensic toxicology, workplace investigations, clinical laboratories, and research on drug transfer. Highly sensitive testing can identify compounds at levels older methods may have missed. That improves surveillance but also increases the need for careful interpretation.

As analytical technology becomes more sensitive, the difference between “detectable” and “meaningful exposure” becomes more important. A laboratory may identify a chemical at a very low concentration. Experts must then assess whether the finding fits intentional administration, environmental transfer, a contaminated product, laboratory error, or another explanation.

The issue also connects to mislabeled or contaminated performance products. Products sold outside regulated pharmaceutical channels may contain an undeclared anabolic steroid or a compound different from the label. GLP1Place’s research on documented versus anecdotal compound safety evidence describes the same broader evidence problem in another market: product claims may not match independently verified testing.

These concerns do not justify buying, using, or handling unverified anabolic products. They explain why researchers and laboratories study trace exposure: to improve evidence quality and reduce uncertainty, not to provide a workaround for anti-doping rules or medical safeguards.

Researcher takeaways

• Dermal absorption is analytically measurable. A single 50-microgram forearm application produced urinary evidence for both tested steroids.
• Metabolites may matter more than the parent steroid. Epitrenbolone was the main trenbolone marker, while a sulfoconjugated metenolone metabolite persisted longest in one participant.
• Detection windows are conditional. The reported three-day and more-than-seven-day findings apply to the study conditions, not every possible exposure.
• Accidental exposure requires case-specific review. The study supports plausibility assessment but does not prove that contamination caused any particular positive test.
• Highly sensitive testing increases interpretive responsibility. Better detection must be paired with validated methods, reference data, and transparent procedures.

Bottom line

The September 18, 2026 study adds evidence to anabolic-steroid detection science. It found that a controlled 50-microgram dermal exposure to trenbolone or metenolone could produce detectable urinary compounds in healthy men. Trenbolone’s main metabolite, epitrenbolone, was detectable for up to three days, while one metenolone metabolite remained detectable for more than a week in one volunteer.

The key conclusion is narrow: dermal exposure can produce urinary evidence under controlled conditions, and laboratories have more data for evaluating route-of-exposure claims. The study does not establish a universal detection window, a safe exposure level, or the cause of any individual result.

For athletes, laboratories, and researchers, the paper reinforces the need to distinguish chemical possibility from real-world probability. That distinction is central to fair anti-doping decisions and responsible interpretation of anabolic-steroid research.

Frequently asked questions

What did the new trenbolone dermal exposure study find?

The study found that a single 50-microgram dermal exposure to trenbolone produced detectable urinary compounds in all participants, with the main metabolite epitrenbolone detectable for up to three days. A single metenolone exposure also produced detectable urinary metabolites, including one that remained measurable for more than a week in one participant.

Does skin contact with trenbolone automatically cause a positive doping test?

No. The study shows that controlled dermal exposure can produce detectable urinary findings, but it does not show that ordinary contact or casual environmental exposure will automatically cause a positive test. Detection depends on the amount transferred, the route, timing, laboratory sensitivity, metabolism, and the specific analytical findings.

What is epitrenbolone?

Epitrenbolone is a major urinary metabolite of trenbolone. A metabolite is a chemical produced when the body processes a drug or steroid. The study found epitrenbolone was the predominant urinary marker after dermal trenbolone exposure.

Are trenbolone and metenolone prohibited in sport?

Yes. Trenbolone and metenolone are listed as prohibited anabolic-androgenic steroids under the World Anti-Doping Code. They are prohibited at all times, both in and out of competition.

How long can dermal trenbolone be detected in urine?

In the study, trenbolone-related findings were detectable for up to three days after the controlled 50-microgram application. This is a study-specific result, not a universal detection guarantee. Different doses, formulations, skin conditions, laboratories, and individuals can change the window.

Does this study prove that positive steroid tests are caused by contamination?

No. The study provides reference data that can help evaluate whether a claimed dermal exposure is chemically plausible. It does not determine whether a particular athlete intentionally used a steroid, nor does it establish that a positive result came from contamination.